Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for Grade I Acute GVHD
NCT00726375Phase 3Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- May 2008
- Primary completion
- Jul 2013
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of etanercept in Acute Graft-Versus-Host Disease (aGvHD), sponsored by University of Michigan Rogel Cancer Center. Started May 2008; status: completed.
02
Drugs
etanercept
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00726375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00726375.